Navigation Links
Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial

EMERYVILLE, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Bionovo, Inc.'s lead drug candidate, MF101, showed positive Phase 2 results for the treatment of hot flashes associated with menopause. Two hundred and seventeen women were enrolled in the company's double-blind, placebo- controlled, randomized Phase 2 trial. Postmenopausal women with 50 or more moderate to severe hot flashes per week were randomized to one of three treatment groups receiving MF101 (5 grams/day), MF101 (10 grams/day), or placebo for twelve weeks. The trial was led by Dr. Deborah Grady at the University of California, San Francisco and was conducted at six medical centers in the United States: University of California, San Francisco, University of Minnesota, Minneapolis, University of Pittsburgh, University of Tennessee, Memphis, University of Alabama, Birmingham and the San Diego Medical Center for Clinical Research.

Bionovo's primary objectives in the Phase 2 clinical trial were to assess the safety, tolerability and the potential efficacy of two doses of MF101 to reduce the frequency and severity of hot flashes. Both doses of MF101 were more effective than placebo at reducing the frequency and severity of hot flashes from the start of the trial until the end of the treatment period 12 weeks later. In a paired t-test, comparing the number of hot flashes per day after 12 weeks of treatment, MF101 5 gm was better than placebo at 12 weeks but did not reach statistical significance (p=0.06). The higher dose was statistically superior to placebo with a p value of 0.05 and both doses combined were superior to placebo with a p value of 0.04. MF101 showed a trend for improvement in severity of hot flashes compared to placebo with the higher dose showing greater improvement (p=0.1) than the lower dose (p=0.12) and with both doses combined superior to placebo (p=0.08). There was a dose response trend suggesting that the higher dose of MF101 was more effective at reducing both frequency and severity of hot flashes than the lower dose.

In secondary analyses, the percent of women reporting greater than 50% reduction in all hot flashes was statistically significantly higher in the MF101 high dose group compared to placebo (p=0.03) and in both doses of MF101 combined compared to placebo (p=0.05).

MF101 is a novel estrogen receptor beta agonist that is expected not to stimulate the endometrium or breast tissue. Safety analyses showed no cases of endometrial hyperplasia or uterine cancer during the trial and there were no differences in incidence of vaginal bleeding between the placebo group and the two cohorts treated with MF101. The only side effect that increased with MF101 treatment was loose stool/diarrhea (12% in each of the drug arms vs. 3% in placebo arm). Constipation was improved with MF101 therapy. These observations are consistent with the presence of soluble fiber in the drug extract, which future optimization of the manufacturing process will significantly reduce. Adherence to the study medication was high with 91% of the participants compliant with treatment after 12 weeks of therapy.

"I am very encouraged and pleased by the findings of this clinical trial," said Deborah Grady, M.D., Associate Dean for Clinical and Translational Science, Professor of Medicine and Director of the University of California, San Francisco (UCSF) Women's Health Clinical Research Center. "The combination of a trend to better efficacy with a higher dose of MF101 and a very strong safety profile of a drug that was very well tolerated by menopausal women is exciting news. These early positive clinical results are not only encouraging for discovering a safer therapy for hot flashes but also support the role of estrogen receptor beta as a novel target for treating menopausal symptoms."

"Recent clinical trials, such as the HERS and the WHI, elucidated important safety concerns of postmenopau sal hormone therapy and resulted in significantly fewer women using these products," said Isaac Cohen, CEO of Bionovo. "For this reason, it is important for us to find safer alternatives for treating menopausal symptoms. The favorable dose response trend signals that MF101 may become a clear alternative to traditional postmenopausal hormone therapy for relief of vasomotor symptoms. We are excited by the prospect of moving forward with the development of a product that could potentially have such broad reach and positively affect the quality of life for millions of women and their loved ones. This first Phase 2 trial conducted by Bionovo serves as a proof of our drug development strategy and we look forward to advancing MF101 into registration trials."

About MF101

MF101 is an estrogen receptor (ER) beta selective drug developed as an alternative to postmenopausal hormone products currently on the market, which are both ER beta and ER alpha agonists that have been shown to increase the risk for breast and uterine cancers. It has been shown that the increased risk of breast and uterine cancers is associated with ER alpha activation and that ER beta blocks the growth promoting effects on breast cancer cells. Bionovo recognized the opportunity to commercialize a product that would be equally effective, with an improved safety profile compared to traditional hormone therapy. The clinical trial results have been evaluated by an independent Data and Safety Monitoring Board and the drug candidate has passed through a standard two-phase examination for safety.

Bionovo, Inc.

Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company has two drugs in clinical testing. MF101 has completed Phase 2 for quality of life conditions associated with menopause, and BZL101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancreatic cancer and other menopausal symptoms. The company is developing its products in close collaboration with leading U.S. academic research centers including: University of California, San Francisco, University of California, Davis, and the University of Colorado Health Sciences Center. For further information please visit:

Forward-Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

    Company Contacts:

    Bionovo, Inc.

    Jim Stapleton

    Chief Financial Officer

    Phone:  510.420.4180



    Katherina Audley

    Phone: 415.847.7295

CONTACT: Jim Stapleton, Chief Financial Officer, +1-510-420-4180,, or Media, Katherina Audley, +1-415-847-7295,, both of Bionovo, Inc.

Web site:

Ticker Symbol: (NASDAQ-NMS:BNVI)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  The American Academy of ... (ACOG), and the March of Dimes cheered today,s ... Our Infants Act of 2015 (S.799), which ... newborns born exposed to drugs, such as opioids, ... introduction, all three organizations have worked together leading ...
(Date:11/25/2015)... On Tuesday, November 24, 2015, the ... Wright Medical Technology, Inc. for product liability and ... implant device, awarded $11 million in favor of ... and three days of deliberations, the jury found ... designed and unreasonably dangerous, and that Wright Medical ...
(Date:11/25/2015)... , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused on ... of various clinical conditions, today announced the closing of ... Depository Shares ( ADSs ), each representing 20 ordinary ... to 3,158,900 ADSs. The ADSs and warrants were issued ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... November 28, 2015 , ... Safe storage for contraceptive devices may not ... from Lakewood, New Jersey and the other from Bradley Beach, New Jersey, there is ... the expense of having to replace NuvaRings more often than necessary. As such, it ...
(Date:11/28/2015)... Aliso Viejo, CA (PRWEB) , ... November 28, 2015 , ... ... 30 new fully customizable media panels to choose from, the possibilities are endless. Users ... angle, and more. With the ProPanel: Pulse masking effects, users are sure to get ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... new study carried out by the University of Toronto and the University of British ... number of hospitalizations for head injuries. The article explains that part of the reason ...
(Date:11/27/2015)... ... , ... A team of Swiss doctors has released a report on mesothelioma ... posted the findings on the website. Click here to read the details now. ... patients who were treated with chemotherapy followed by EPP surgery. Among the 106 patients ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a ... customers 10% off of their purchase of lice treatment product. In addition, customers will ... to a company spokesperson. “Finding lice is a sure way to ruin the holidays, ...
Breaking Medicine News(10 mins):